445041-75-8 Usage
Uses
Used in Pharmaceutical Industry:
BR5QP is used as a pharmaceutical candidate for the development of new drugs due to its anti-inflammatory and anticancer properties. Its potential therapeutic applications make it a promising compound for the treatment of cancer and inflammatory diseases.
Used in Cancer Treatment:
BR5QP is used as an anticancer agent, targeting various types of cancer. Its anti-inflammatory and anticancer properties make it a promising candidate for the development of new cancer treatments.
Used in Inflammatory Disease Treatment:
BR5QP is used as an anti-inflammatory agent, targeting various inflammatory diseases. Its anti-inflammatory properties make it a promising candidate for the development of new treatments for inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 445041-75-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,5,0,4 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 445041-75:
(8*4)+(7*4)+(6*5)+(5*0)+(4*4)+(3*1)+(2*7)+(1*5)=128
128 % 10 = 8
So 445041-75-8 is a valid CAS Registry Number.
445041-75-8Relevant academic research and scientific papers
PROCESS FOR THE PREPARATION OF (2R)-2-[4-(7-BROMO-2-QUINOLYLOXY)PHENOXY]PROPANOIC ACID
-
Page/Page column 11, (2009/03/07)
Industrially applicable process for preparing (2R)-2-[4-(7-bromo-2-quinolyloxy)phenoxy] propanoic acid, and salts thereof.
Antitumor agents
-
, (2008/06/13)
The invention provides compounds of formula I: wherein Y is F, Cl, Br, methyl or methoxy; and pharmaceutically acceptable salts thereof. The compounds are effective antitumor agents. The invention also provides pharmaceutical compositions comprising a com
II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxylphenoxy}propionic acid (XK469)
Hazeldine, Stuart T.,Polin, Lisa,Kushner, Juiwanna,White, Kathryn,Bouregeois, Nicole M.,Crantz, Brianna,Palomino, Eduardo,Corbett, Thomas H.,Horwitz, Jerome P.
, p. 3130 - 3137 (2007/10/03)
XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor me
